 Oncternal Therapeutics, Inc. Nasdaq: ONCT, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the ongoing Phase 12 CIRLL Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma clinical trial, in which cirmtuzumab, an investigational anti-ROR1 monoclonal antibody, is being evaluated in combination with ibrutinib in patients with mantle cell lymphoma MCL or chronic lymphocytic leukemia CLL. The data will be presented as part of the American Society of Clinical Oncology ASCO 2020 Virtual Annual Meeting, and a copy of the poster presentation will be available online at on May 29, 2020: 